Primary Thrombocytopenic Purpura and Acquired Hemolytic Anemia

Evans, Robert S.; Takahashi, Kazuyuki; Duane, Rose T.; Payne, Rose; Liu, Chi-Kong

doi:10.1001/archinte.1951.03810010058005

Cited by 427 publications

(210 citation statements)

References 22 publications

Supporting

Mentioning

195

Contrasting

Unclassified

Order By: Relevance

“…1 Mortality is high in the 4 reported pediatric series, ranging from 7-36%. [2][3][4][5] Only a few non-controlled trials of treatment regimens containing a small number of patients with ES have been published.…”

confidence: 96%

Rituximab therapy for childhood Evans syndrome

Bader-Meunier¹,

Aladjidi²,

Bellmann³

et al. 2007

Haematologica

View full text Add to dashboard Cite

The safety and efficacy of rituximab have been retrospectively assessed in 17 children with Evans syndrome. Patients received 4 or 3 weekly doses of rituximab (375 mg/m 2 per dose) associated with prednisone, alone (14 patients) or associated with other immunosuppressive drugs. Complete or partial remission of at least one cytopenia was achieved in 13 out of the 17 patients (76%), and lasted in 11 of them with a mean follow-up of 2.4 years (range 0.5-7 years). Steroid therapy was stopped or tapered at 50-100% of the baseline dosage in all long-term responders. Moderate side effects and infection occurred only in 4 and 1 children respectively.Key words: Evans syndrome, children, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rituximab.

show abstract

confidence: 96%

Rituximab therapy for childhood Evans syndrome

Bader-Meunier¹,

Aladjidi²,

Bellmann³

et al. 2007

Haematologica

View full text Add to dashboard Cite

show abstract

“…IMHA and ITP Evans syndrome, defined as the combined or sequential occurrence of IMHA and ITP, was first reported by Evans et al in 1951 and is a rare disease in humans (Evans et al 1951). The prevalence of Evans syndrome in dogs has been estimated at 0.01% (Orcutt et al 2010).…”

Section: Differential Diagnosismentioning

confidence: 99%

Canine idiopathic immune-mediated haemolytic anaemia: a review with recommendations for future research

Piek

2011

Veterinary Quarterly

View full text Add to dashboard Cite

“…5 A few decades later, in 1951, Harrington observed a child with transient purpura born to a mother with ITP and suspected that the passage of a humoral factor from mother to child was responsible for platelet destruction. 6 In the same year, Evans hypothesized that the ITP had an immune genesis, 7 paving the way to immunosuppressants as an effective treatment for this disorders. 8 Finally, the search for the humoral substance responsible for causing the platelet count to rise in response to thrombocytopenia, which had involved many groups of researchers for many decades, led in 1994 to the purification and cloning of thrombopoietin (TPO).…”

mentioning

confidence: 99%